Co announces that the FDA has granted approval for the co's Abbreviated New Drug Applications to market Ondansetron Hydrochloride Tablets, 4 mg, 8 mg and 24 mg and Ondansetron Orally Disintegrating ...
Products: All lots of Accel-Ondansetron ODT (4 mg and 8 mg tablets); Mint-Betahistine (8 mg, 16 mg and 24 mg tablets); PMS-Pirfenidone (267 mg and 801 mg tablets) ...
Editor's Note: According to the FDA Web site, on Nov. 29, 2005, the FDA's Center for Drug Evaluation and Research (CDER) rescinded the Nov. 18, 2005, approval of Kali Laboratories' ANDA 76-506 for ...
Another randomized multicenter study was conducted by Seynaeve and collegues [4] and included 535 chemotherapy- naive patients receiving cisplatin, 50-120 mg/m 2. Patients were randomized to receive ...
Dec 26 (Reuters) - Par Pharmaceutical Cos. Inc. said it got U.S. regulatory approval for the generic version of GlaxoSmithKline Plc's Zofran tablets, used for the prevention of chemotherapy-related ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Accel Pharma's ...
Please provide your email address to receive an email when new articles are posted on . The 32-mg, single IV dose of ondansetron hydrochloride no longer will be marketed because of the potential for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback